Intrexon buys laboratory operations from Codexis
Expands presence to Europe and increases bioproduction capabilities and capacity
US synthetic biology company Intrexon Corporation, a leader in synthetic biology, has acquired state-of-the-art laboratory operations in Budapest, Hungary, from Codexis, a developer of biocatalysts for the pharmaceutical and complex chemistry industries.
Intrexon's Industrial Products Division (IPD) is positioned to develop biologically based solutions across a number of sectors: health, food, energy, environment and consumer, including bioproduction of APIs for novel anti-infectives, for example. The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermentation process optimisation and scale-up.
Intrexon's IPD will absorb the Budapest laboratory staff and integrate their expertise with Intrexon's suite of synthetic biology technologies and capabilities. This will allow Intrexon to better serve current collaborators and to attract new opportunities for API and industrial and consumer product collaborations.
"The expansion affords Intrexon greater flexibility in existing collaborations, including Amneal, Johnson & Johnson and Oragenics, and positions the company to meet demand from international collaborators," said Robert F. Walsh, President of Intrexon's Industrial Products Division. "We are pleased to integrate the Budapest team into Intrexon and look forward to their immediate contributions."
"The state-of-the-art industrial development facility and team we have acquired not only expands our current IPD operations, but its location in Budapest will enable us to continue growing our interests abroad and strengthen our ability to service the European and Asian markets," added Peter Seufer-Wasserthal, Vice President of Business Development for Europe and Asia.
